Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of β-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study.
Maddaloni E, Naciu AM, Mignogna C, Galiero R, Amendolara R, Fogolari M, Satta C, Serafini C, Angeletti S, Cavallo MG, Cossu E, Sasso FC, Buzzetti R, Pozzilli P; LADASAXADAPA study group. Maddaloni E, et al. Among authors: cossu e. Diabetes Obes Metab. 2024 May;26(5):1670-1677. doi: 10.1111/dom.15469. Epub 2024 Jan 31. Diabetes Obes Metab. 2024. PMID: 38297915 Clinical Trial.
MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
Mantovani A, Morieri ML, Aldigeri R, Palmisano L, Masulli M, Bonomo K, Baroni MG, Cossu E, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Cas AD, de Kreutzenberg SV, Targher G. Mantovani A, et al. Among authors: cossu e. Diabetes Metab. 2024 Jan;50(1):101497. doi: 10.1016/j.diabet.2023.101497. Epub 2023 Nov 20. Diabetes Metab. 2024. PMID: 37992857 Free article.
Validation in type 2 diabetes of a metabolomic signature of all-cause mortality.
Copetti M, Baroni MG, Buzzetti R, Cavallo MG, Cossu E, D'Angelo P, Cosmo S, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Savino AF, Trischitta V. Copetti M, et al. Among authors: cossu e. Diabetes Metab Res Rev. 2024 Feb;40(2):e3734. doi: 10.1002/dmrr.3734. Epub 2023 Oct 15. Diabetes Metab Res Rev. 2024. PMID: 37839040
Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus.
Csermely A, Mantovani A, Morieri ML, Palmisano L, Masulli M, Cossu E, Baroni MG, Bonomo K, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Aldigeri R, Cas AD, de Kreutzenberg SV, Targher G. Csermely A, et al. Among authors: cossu e. Diabetes Metab. 2023 Nov;49(6):101477. doi: 10.1016/j.diabet.2023.101477. Epub 2023 Sep 12. Diabetes Metab. 2023. PMID: 37708990
Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus.
Mantovani A, Morieri ML, Palmisano L, Masulli M, Cossu E, Baroni MG, Bonomo K, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Aldigeri R, Cas AD, de Kreutzenberg SV, Targher G. Mantovani A, et al. Among authors: cossu e. Cardiovasc Diabetol. 2023 Aug 10;22(1):204. doi: 10.1186/s12933-023-01945-x. Cardiovasc Diabetol. 2023. PMID: 37563618 Free PMC article.
Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.
Sordi V, Monti P, Lampasona V, Melzi R, Pellegrini S, Keymeulen B, Gillard P, Linn T, Bosi E, Rose L, Pozzilli P, Giorgino F, Cossu E, Piemonti L. Sordi V, et al. Among authors: cossu e. Front Endocrinol (Lausanne). 2023 Jun 20;14:1175640. doi: 10.3389/fendo.2023.1175640. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37409229 Free PMC article. Clinical Trial.
106 results